OR WAIT null SECS
ERS Genomics and Bioneer have revealed the signing of a license agreement for access to CRISPR/Cas9 genome editing technology intellectual property.
In a June 4, 2019 press statement, ERS Genomics and Bioneer have revealed the signing of a license agreement for access to CRISPR/Cas9 genome editing technology intellectual property.
The terms of the agreement will enable Bioneer to use ERS Genomics’ technology to generate a range of innovative human cell-based disease models, which will broaden its core capabilities and expand on its expertise in biomedical research support. Financial terms of the agreement were not disclosed.
“Bioneer has proven expertise in a broad array of biomedical fields. Adding CRISPR/Cas9 to their toolbox ensures they remain on the leading edge of technology,” said Eric Rhodes, CEO of ERS Genomics, in the press statement. “We are very pleased that Bioneer chose to expand on its service offering by licensing CRISPR/Cas9 technology through ERS Genomics.”
“This cutting-edge technology will complement Bioneer’s competences in advanced preclinical disease modeling,” added Lars H. Pedersen, CEO of Bioneer.
Christian Clausen, CSO of Bioneer, said, “Bioneer is working with both industry and academia to solve complex disease relevant questions by using advanced disease modeling. The CRISPR/Cas9 tools will enable clients and collaborators to precisely tailor their preclinical modeling strategies to their specific needs for predictive in vitro models.”
Source: ERS Genomics